NCT03134183View on ClinicalTrials.gov

24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 19, 2016

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2017

Conditions
Abortion, Second Trimester
Interventions
DRUG

Vaginal Misoprostol

Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E

DRUG

Buccal Misoprostol

Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER

NCT03134183 - 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E | Biotech Hunter | Biotech Hunter